Lupin Limited (LUPIN) breaks below support, falling -5% to ₹2239.0 on the NSE on 10 Aug 2026. The move comes as the stock has broken below its 6-month support trendline, which ended at ₹2418.29. This breakdown indicates a shift in momentum, with the stock now trading 8.01% below this critical support level. In the healthcare sector, particularly among drug manufacturers, this move suggests company-specific pressures rather than broad sector trends, given the strong fundamental backdrop of the company.

Technical setup — trendlines & DMA

From a technical perspective, LUPIN is currently in a breakdown phase, having fallen below its 6-month support trendline of ₹2418.29. The stock is now trading 8.01% below this level, indicating a potential shift in sentiment. The 6-month resistance trendline stands at ₹2517.66, which is 12.45% above the current price, suggesting a significant gap to the upside if the stock were to recover. The 50-DMA at ₹2378.4 remains above the 200-DMA at ₹2247.3, indicating a bullish longer-term trend, though the stock is currently testing the 50-DMA. LUPIN is trading in the middle third of its 52-week range, which spans from ₹1855.0 to ₹2529.5, implying that there is room for both upside and downside within this range.

Fundamentals & business context

Despite the technical breakdown, LUPIN’s fundamental picture remains robust. The company boasts a PE ratio of 20.3, which, given its 19.1% profit margin and 19.1% revenue CAGR over the past five years, suggests that the market is pricing in solid growth expectations. The 131.5% profit CAGR over the same period underscores the company’s strong earnings trajectory. With 34.7% institutional ownership, there is a clear vote of confidence from sophisticated investors. There were no specific NSE catalysts today, indicating that the move is likely driven by technical factors rather than new fundamental information.

Algorithmic scorecard

The algorithmic scorecard for LUPIN reflects a balanced but slightly technically challenged position. The overall score of 78 indicates a strong fundamental base with some technical concerns. The two strongest signals are the company’s revenue CAGR of 19.1% and its profit CAGR of 131.5%, which highlight robust growth and improving profitability. Additionally, the PEG ratio of 0.15 suggests that the stock is undervalued relative to its growth rate, making it an attractive buy on a fundamental basis. On the weaker side, the negligible dividend yield of 0.75% offers little income for investors seeking regular returns. Furthermore, the stock’s current position below the 50-DMA, despite the bullish longer-term trend, indicates short-term technical pressure that investors should monitor.

Company outlook

Management’s outlook for FY27 is cautiously optimistic. They expect top-line growth in the high-single digits with margins around 25%, despite increased headwinds. The U.S. business is projected to sustain billion-dollar-plus revenues, with new product launches offsetting some erosion. The VISUfarma acquisition is expected to add Euro 50-60 million in sales and 25% margin, with potential to cross USD 100 million in two to three years. Biosimilars are anticipated to be a meaningful revenue contributor, with each product significantly impacting the P&L. The Semaglutide launch in India has been solid, with good market acceptance and potential to become a Top 3 player in the generic Semaglutide market. The company plans to launch over 50 products in the U.S. in the next three years, including 10 exclusive first-to-files, four biosimilars, and two to three 505(b)(2)s. They also intend to expand their specialty portfolio through organic initiatives and targeted acquisitions, and launch an oral tablet product in India later this financial year. Multiple product filings and launches are planned, including Ravicti®, Saxenda®, Sacubitril Valsartan, Rivaroxaban, Pegfilgrastim, Ranibizumab, Aflibercept, and Etanercept. Additionally, the company is working on green propellant MDIs with potential for a generic launch.

Get all details on LUPIN — P&L, peers, shareholding and more on TradeAlone.